OBJECTIVES: To evaluate the prevalence of transmitted drug resistance (TDR) and non-B subtypes in patients with acute/recent HIV-1 infection in Barcelona during the period 1997-2012. METHODS: Patients from the "Hospital Clinic Primary HIV-1 Infection Cohort" with a genotyping test performed within 180 days of infection were included. The 2009 WHO List of Mutations for Surveillance of Transmitted HIV-1 Drug Resistance was used for estimating the prevalence of TDR and phylogenetic analysis for subtype determination. RESULTS: 189 patients with acute/recent HIV-1 infection were analyzed in 4 time period...
Objectives: Transmitted HIV-1 drug resistance (TDR) can reduce the efficacy of first-line antiretrov...
Background Molecular surveillance of newly diagnosed HIV-infections is important for tracking trend...
peer reviewedBackground : One out of ten newly diagnosed patients in Europe was infected with a viru...
OBJECTIVES: To evaluate the prevalence of transmitted drug resistance (TDR) and non-...
To evaluate the prevalence of transmitted drug resistance (TDR) and non-B subtypes in patients with ...
OBJECTIVES: To evaluate the prevalence of transmitted drug resistance (TDR) and non...
Objectives: We estimated the prevalence of transmitted-drug-resistance-associated mutations (TDRAMs)...
<p>Fig 1A: Prevalence of transmitted drug resistance mutations by study period and drug family accor...
Most of the non-B HIV-1 subtypes are predominant in Sub-Saharan Africa and India although they have ...
[Abstract] To describe temporal trend and characteristics of newly HIV-diagnosed patients in a medic...
International audiencePrimary HIV-1 infections (PHI) with non-B subtypes are increasing in developed...
OBJECTIVES: Transmitted HIV-1 drug resistance (TDR) can reduce the efficacy of first-line antiretrov...
OBJECTIVES: Transmitted HIV-1 drug resistance (TDR) can reduce the efficacy of first-line antiretro...
Objectives: Transmitted HIV-1 drug resistance (TDR) can reduce the efficacy of first-line antiretrov...
Background Molecular surveillance of newly diagnosed HIV-infections is important for tracking trend...
peer reviewedBackground : One out of ten newly diagnosed patients in Europe was infected with a viru...
OBJECTIVES: To evaluate the prevalence of transmitted drug resistance (TDR) and non-...
To evaluate the prevalence of transmitted drug resistance (TDR) and non-B subtypes in patients with ...
OBJECTIVES: To evaluate the prevalence of transmitted drug resistance (TDR) and non...
Objectives: We estimated the prevalence of transmitted-drug-resistance-associated mutations (TDRAMs)...
<p>Fig 1A: Prevalence of transmitted drug resistance mutations by study period and drug family accor...
Most of the non-B HIV-1 subtypes are predominant in Sub-Saharan Africa and India although they have ...
[Abstract] To describe temporal trend and characteristics of newly HIV-diagnosed patients in a medic...
International audiencePrimary HIV-1 infections (PHI) with non-B subtypes are increasing in developed...
OBJECTIVES: Transmitted HIV-1 drug resistance (TDR) can reduce the efficacy of first-line antiretrov...
OBJECTIVES: Transmitted HIV-1 drug resistance (TDR) can reduce the efficacy of first-line antiretro...
Objectives: Transmitted HIV-1 drug resistance (TDR) can reduce the efficacy of first-line antiretrov...
Background Molecular surveillance of newly diagnosed HIV-infections is important for tracking trend...
peer reviewedBackground : One out of ten newly diagnosed patients in Europe was infected with a viru...